Lundbeck and Otsuka expand collaboration relating to Abilify
Lundbeck and Otsuka now expand their existing collaboration to include promotion of Abilify (aripiprazole) in 14 European countries starting April 1, 2013. Under the agreement, Otsuka and Lundbeck will jointly promote Abilify in Denmark, Finland, Germany, Italy, Spain, Sweden and the United Kingdom. Lundbeck will promote Abilify in Austria, Belgium, Ireland, Netherlands, Poland, Portugal and Romania. The agreement provides Lundbeck with the rights to promote all formulations of Abilify that are currently being marketed, sold and distributed by Otsuka in the European Union including the swallowable tablet, oral solution, orally-disintegrated tablet and the intramuscular rapid injectable.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
2 mins